Natera
NTRA · NASDAQ · Healthcare
$390.79
+$21.26 (+5.44%) today
Market Cap
$56.33B
24h Volume
$657.0M
P/E Ratio
-78.2
52w High
$390.79
52w Low
$160.21
Est. AI Revenue
20%
7-Day Sparkline (Static)
Company facts
Performance
About Natera
Natera is a genetic testing company. It sells diagnostics built on cell-free DNA, fragments of DNA circulating in blood, serving oncology, prenatal care, and organ transplant medicine, and earns revenue on test volumes.
Machine learning is what makes its tests work. Signatera detects tiny traces of circulating tumor DNA to monitor cancer, Panorama uses AI-driven analysis for prenatal screening, and Prospera applies the same approach to detecting organ transplant rejection early.
Founded in 2004 and headquartered in Austin, Texas, Natera trades on the NASDAQ and employs about 6,100 people under CEO Steve Chapman.
Natera in the AI buildout
Natera sits in the AI Healthcare layer, where machine learning is the scientific engine rather than a bolt-on feature. Its algorithms extract faint genetic signals from blood samples, which is what makes tests like Signatera and Panorama possible at all. Even so, the business grows on diagnostic test volumes, clinical adoption, and reimbursement, not on AI buildout spending. Supercycle gives it an AI Exposure Score of 15 out of 100.
NTRA is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
NTRA trades at $390.79, 100% of the way up its 52-week range of $160.21 to $390.79.
Market cap
Market capitalization is $56.33B, with an AI Exposure Score of 15 out of 100.
Next earnings
Natera is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Natera do?
Natera sells genetic tests based on cell-free DNA analysis, serving cancer monitoring, prenatal screening, and organ transplant medicine, and earns revenue on diagnostic test volumes.
How is Natera exposed to AI?
AI is core to its science, not its market. Machine learning makes its tests accurate, but growth depends on test volumes and clinical adoption. Supercycle scores it 15 out of 100.
What are Natera's main products?
Signatera for circulating tumor DNA cancer monitoring, Panorama for AI-driven prenatal screening, and Prospera for detecting organ transplant rejection.
Where is Natera headquartered and who leads it?
Natera is headquartered in Austin, Texas, was founded in 2004, and is led by CEO Steve Chapman. It employs about 6,100 people and trades on the NASDAQ.
Is NTRA a pure play AI stock?
No. Natera is a diagnostics company where machine learning powers the assays. Its AI Exposure Score of 15 out of 100 reflects AI as enabling science rather than the growth driver.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.